Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

vismodegib

Roche, social media and patients – part 2

Patient groups talk about their use of social media and the challenges they face

- PMLiVE

EFPIA says “indiscriminate” data transparency could be harmful

Comments come as European Parliament prepares to discuss clinical trial overhaul

Roche, social media and patients – part 1

UK pharma company talks about its digital patient group summit Share+

- PMLiVE

Researcher calls for Roche boycott over missing Tamiflu data

Nordic Cochrane Centre's Peter Gøtzsche also wants European governments to sue the pharma company for withholding data

- PMLiVE

New hope for castration-resistant prostate cancer

An unprecedented number of therapies have reached late-stage clinical trials or been approved over recent years targeting this disease with an unmet medical need

- PMLiVE

Good practice in cancer care recognised at UK awards

Sir Mike Richards honoured with lifetime achievement award at QiC Excellence in Oncology 2012

- PMLiVE

India revokes Roche’s Pegasys patent after patient group challenge

Company becomes latest in big pharma to see intellectual property overturned

- PMLiVE

Roche’s Avastin cleared in EU for recurrent ovarian cancer

Becomes first biologic to win approval for platinum-sensitive ovarian cancer

- PMLiVE

Discounts persuade NICE to recommend skin cancer drugs Yervoy and Zelboraf

Roche and BMS offer patient access schemes for NHS use of drugs

- PMLiVE

BMJ to only publish trials with open data

Comes as journal pushes Roche for full data on Tamiflu

- PMLiVE

Menarini signs €800m cancer antibody deal

Will work with Oxford BioTherapeutics on antibody-drug conjugates

- PMLiVE

FDA approves Teva’s leukaemia drug Synribo

Accelerated approval means early competition for Pfizer’s Bosulif

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links